Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

April 25, 2023

NASDAQ US Health Care Life Sciences Tools and Services earnings 61 min

Earnings Call Speaker Segments

Sallilyn Schwartz

executive
#1

Hello everyone, and thank you for being here on the call about our Q1 2023 results. During this session, we'll review the financial figures we published once the market closed, offer our thoughts on how the business has been performing commercially, and then take your questions. If you haven't had a chance to look at the earnings release yet, it's available on the Investor Relations section of illumina.com. With us from Illumina are President and Chief Executive Officer Francis deSouza, and Joydeep Goswami, who is our Chief Financial Officer as well as Chief Strategy and Corporate Development Officer. Francis will provide an update on how things are going at Illumina, and Joydeep will take us through the financial results, which include GRAIL. As a quick reminder, interim measures ordered by the European Commission barred our purchase of GRAIL under the EU merger regulation, so GRAIL must be kept and run as a separate, independent entity from Illumina. This call is being recorded, and the audio portion will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity made on today's call to be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. What we actually achieve could end up looking quite different from what we project or talk about here. Every statement looking ahead rests on information we have right now, and Illumina isn't on the hook to revise any of those statements later. If you want a clearer picture of the risks and uncertainties that might make real outcomes come out differently, take a look at what Illumina submits to the Securities and Exchange Commission — that includes our latest Forms 10-Q and 10-K. Having said all that, I'll hand things over now to Francis.

Francis deSouza

executive
#2

Thanks, Salli. Hi, everyone, and good afternoon. In the first quarter, Illumina brought in revenue of roughly $1.09 billion, along with diluted non-GAAP EPS of $0.08 — both of which came in above the guidance we gave at the start of the year, though as anticipated they declined relative to the prior year. Later in this call, Joydeep will walk you through additional specifics. For the remainder of the year, our aim is to produce sequential growth, mainly by expanding manufacturing and distribution of NovaSeq X, generating elasticity from its enhanced capabilities, and lifting margins. We'll provide more detail on each of those; during Q1 we hit important product milestones, among them the shipment of the initial NovaSeq X systems. In addition, we introduced Illumina Complete Long-Read technology as well as Illumina Connected Insights, a cloud-based tertiary analysis tool that tackles a major obstacle to adoption and will let additional labs carry out comprehensive genomic profiling for advanced tumors. Now to how we performed across platforms, starting with high throughput. With the NovaSeq X launch, Illumina's competitive standing in high-throughput sequencing was further reinforced. Global interest in the NovaSeq X Series remained strong during Q1, and as the quarter closed we had received over 200 orders spanning more than 30 countries. Clinical demand kept surpassing expectations, accounting for about 40% of orders, with certain customers intending to use the NovaSeq X to introduce new clinical offerings. Roughly 15% of orders come from customers new to high throughput, such as the clinical genomics lab drawing on NovaSeq X's ease of use and cost advantages to run high-throughput whole genome, single cell and RNA sequencing. Our ability to manufacture NovaSeq X instruments and consumables is ramping up well; during Q1 we shipped 67 NovaSeq X instruments, exceeding our initial expectation of 40 to 50, and we now anticipate delivering over 330 NovaSeq X instruments this year, an increase from 300. Early runs by customers are demonstrating strong data output and sequencing quality, with some reporting outputs above 7 terabases and over 95% of bases above Q30, considerably better than public specifications. As customers receive their NovaSeq Xs and map out their deployments, they're providing examples of how the NovaSeq X will release demand elasticity in the sequencing market. Customers intend to take advantage of the X's higher output and reduced price per sample in order to sequence additional samples, run additional analyses per sample and generate additional data per analysis. To illustrate, a top European life science research institute will rely on NovaSeq X to expand its data-intensive research programs, particularly in multiomics, spatial and single cell, which will allow them to deliver Atlas scale projects. Among our clinical customer base, the higher output and cost savings from NovaSeq X are being used to introduce new sequencing-intensive offerings. Some of our accounts are going to move away from targeted panels and adopt exomes and genomes instead, since that gives them better diagnostic yield along with more efficient health care. In oncology, meanwhile, customers are looking to the X for launching liquid biopsy testing, and that requires 12 to 15x the sequencing that solid tumor testing does. Several clients are taking the money they save and the quicker turnaround they get and using those advantages to step up to more advanced sequencing applications, including minimal residual disease, or MRD, which lets them build large-scale data sets. At the same time, interest in NovaSeq 6000 held steady, mostly for growing the fleets of existing workflows, and in Q1 we shipped 17 NovaSeq 6000 units. More than 80% of NovaSeq 6000 shipments went to clinical buyers, and about 25% of those shipments were for oncology testing. On the mid-throughput side, NextSeq 1000 and 2000 unit shipments increased 6% year over year, as customers either expand their existing fleets or continue shifting projects off the MiSeq and NextSeq 550. In Q1, more than 20% of NextSeq 1000 and 2000 units were sold to customers who are new to Illumina. Our win rate in the mid-throughput category remains strong, although some sales cycles are lengthening. Our low-throughput instruments continue to serve as an entry point into sequencing. Roughly 30% of those first-quarter shipments went to customers new to Illumina, which further expands our installed base and helps drive sequencing adoption across a broad customer network. Turning to our clinical markets. For Illumina, Q1 represented a key milestone, as clinical sequencing consumables revenue made up 50% of our total sequencing consumables revenue for the first time. During Q1, oncology testing consumables fell 3% versus the prior year, yet climbed 21% quarter over quarter, fueled by rising clinical testing volumes and greater product development in fields such as liquid biopsy and MRD. Certain customers in this segment face pressure to boost profitability, which could in turn hinder their capacity to create new tests and scale. Revenue from our market-leading TruSight Oncology assay, TSO 500, surpassed $25 million in the quarter, rising 26% year-over-year across over 540 accounts, propelled by higher utilization and pull-through, especially in Europe. During March, we announced that our collaboration with Myriad Genetics was getting bigger, aimed at broadening availability of homologous recombination deficiency, or HRD, testing. This biomarker matters a lot because it identifies tumors carrying a specific kind of DNA damage — the type seen in ovarian, breast, prostate and pancreatic cancers. The research use-only assay we call TSO 500 HRD is now available across the U.S., and among the first to adopt it is Florida Cancer Specialists & Research Institute, which ranks as one of the largest independent medical oncology and hematological practices in the country. Through this wider partnership, a distinctive alliance has also been formed to advance HRD as a companion diagnostic for novel agents that target such tumors. During this quarter, we achieved significant progress in Europe regarding reimbursement for NGS-based oncology testing, which expanded the available market. In Italy, seven regions allocated EUR 10 million toward next-generation sequencing for lung cancer. Meanwhile, in Germany, health insurers started covering whole genome sequencing for pediatric cancer patients who have relapsed. Additionally, the Czech Republic incorporated funding for comprehensive genomic profiling into its national fee schedule as of January 1. On the oncology side as well, GRAIL saw rising demand during Q1 for its Galleri blood test, which detects multiple cancers early, and generated $20 million in revenue, surpassing expectations and marking 100% growth compared to the same period last year. GRAIL's non-GAAP operating expenses climbed to $173 million, driven mostly by spending on clinical trials and on building out the company's commercial team. Orders for the Galleri test have surpassed 85,000 since it became available, with about 20,000 of them placed during Q1 alone. Enrollment for the NHS-Galleri trial, which involves 140,000 people, closed in July 2022 after a little more than 10 months, and the study is progressing well — more than 50% of participants have returned for their second yearly blood draw. Having reached the midpoint, the trial is currently tracking toward its retention goals. GRAIL also continued to expand its partnerships. Following a successful pilot conducted last year, John Hancock—among the biggest life insurers in the United States and part of Manulife—said it would broaden availability of Galleri for qualifying life insurance policyholders. Meanwhile, Providence, a health system that serves the Western portion of the country, broadened its collaboration with GRAIL so that Galleri could be provided to eligible people throughout its network of 52 hospitals and 900 clinics spanning 7 states. Turning to reproductive health, consumable shipments fell 4% compared with the prior year, largely because of FX, yet rose 14% from the previous quarter thanks to ongoing gains in coverage. Within the U.S., Virginia and Michigan began state Medicaid coverage for NIPT across all pregnancies, which added roughly 4.3 million covered lives and over 70,000 pregnancies annually. Genetic disease testing, also known as GDT, just posted its strongest quarter ever.

Francis deSouza

executive
#3

During the first quarter, GDT consumable shipments increased 7% compared to the same period last year and rose 6% from the prior quarter. For patients suffering from rare and undiagnosed genetic conditions, coverage for whole genome sequencing keeps expanding. In the quarter, a major U.S. health insurer revised its policy so that managed Medicaid members across 16 states would be included, which brought in roughly 3.8 million additional covered lives for whole genome sequencing. Also within GDT, earlier this month, we revealed a collaboration with Henry Ford Health — a Detroit metro-area health care organization and a top American academic medical center — aimed at evaluating how whole genome sequencing might enhance cardiovascular disease management, with special emphasis on diverse and underserved groups. Now moving to our research and applied markets. Shipments of sequencing consumables fell 19% versus a year ago, largely because COVID surveillance has slowed. Considering the full year, we remain on schedule to meet our 2023 financial commitments, along with several significant launches over the next few quarters. More specifically, in Q3 we will ship the ICLR-enrichment assay, a cost-effective high-throughput targeted Long-Reads solution, and during the first half of 2024, SBS chemistry plus NextSeq 1000, 2000, which will bring step change improvements in cost, speed and sustainability on that platform. Lastly, as we steer through this fluid landscape, our attention stays on producing lasting success for shareholders by balancing investment in breakthrough innovations for future growth with generating operating leverage via rigorous expense management throughout the company. With that goal, we shared earlier today our pledge to achieve Core Illumina non-GAAP operating margins of 25% in 2024 and 27% in 2025, all while continuing to invest in the essential components of our innovation road map. Extending the cost-cutting measures unveiled last November, we are implementing further actions to lower our annualized run rate expenses by over $100 million starting later in 2023; this will speed up our path to better margins and also release capital for greater investment in high-growth areas. I'll now hand the call to Joydeep, who will cover further specifics about our results and outlook, and give more information about the measures we're pursuing to achieve the cost reduction I referenced. Joydeep?

Joydeep Goswami

executive
#4

Thanks, Francis. To kick things off, I'll walk through the consolidated financial results, then cover the segment results for Core Illumina and GRAIL, and wrap up with a few more comments about how we see 2023 shaping up. The results I'm going over are non-GAAP, and they include stock-based compensation. Please take a look at the GAAP reconciliation for these non-GAAP measures — it's in today's release as well as the supplementary data posted on our website. Consolidated revenue for the first quarter came in at $1.09 billion, which is a 1% increase over the fourth quarter of 2022 and above the top end of our guidance range, driven by shipments of NovaSeq X that came in stronger than we expected. Compared with the same period last year, consolidated revenue fell 11%, or 9% on a constant currency basis, net of hedging effects; the main drivers were an anticipated year-over-year decline in COVID surveillance, COVID-related disruptions in China, some high-throughput customers moving over to NovaSeq X, and customers navigating tight capital markets around the world. Non-GAAP net income came to $13 million, or $0.08 per diluted share, and that figure includes dilution from GRAIL's non-GAAP operating loss, which was $164 million for the quarter. Our non-GAAP tax rate for the quarter was 27.3%, up from 17.8% in Q1 2022, and both quarters reflect the impact of R&D capitalization requirements. Even though the dollar impact of the non-GAAP tax expense from R&D capitalization requirements was identical in both periods, the effect on our effective tax rate in quarter 1 2023 was larger because our earnings were lower. Our non-GAAP weighted average diluted share count for the quarter was roughly 158 million. Now on to segment results. Core Illumina revenue was $1.08 billion, a 12% decline year-over-year, and that includes an anticipated COVID surveillance headwind of roughly 400 basis points. COVID surveillance brought in about $11 million in total revenue in Q1 2023, versus $60 million in Q1 2022, which works out to a $49 million headwind. Net of hedging effects, Core Illumina revenue was down 10% on a constant currency basis. Core Illumina sequencing consumables revenue was $692 million, up 1% sequentially but down 12% year-over-year, and that includes a COVID surveillance headwind of approximately 500 basis points. Beyond the COVID surveillance slowdown, the year-over-year decline was mainly due to lower NovaSeq 6000 consumables pull-through stemming from the headwinds I mentioned earlier, COVID-related disruptions in China, some high-throughput customers transitioning to NovaSeq X, and customers dealing with constrained capital markets globally. Total sequencing activity across our connected high- and mid-throughput instruments rose 6% from Q4 2022 and 3% year-over-year. Research and applied was up 7% from Q4 2022 and down 4% year-over-year. Clinical sequencing activity growth stayed strong, rising 7% from Q4 2022 and 15% year-over-year. As a reminder, we see this data as a helpful reference that illustrates general activity trends across our installed base and correlates directionally with revenue over time. Sequencing instruments revenue for Core Illumina was $154 million, down 27% year-over-year, including a 300 basis point COVID surveillance headwind. Like we anticipated, the main reason for the decline compared with a year ago was that we shipped fewer NovaSeq 6000 units than we did in a record Q1 2022, along with a drop in mid-throughput shipments, largely because there were fewer NextSeq 550 placements in China. Shipments of NovaSeq X that came in above what we had expected helped make up for part of that impact, though during the first year of launch we are still limited on supply. Demand remained robust for NextSeq 1K, 2K among customers who are new to Illumina. Core Illumina sequencing service and other revenue reached $119 million, which was 7% higher than a year ago, mainly because of increased instrument service contract revenue on a larger installed base. Before I turn to the regional results for Core Illumina, I want to point out that we have put a new global commercial structure in place so we can operate more efficiently and line up better with local markets; we have combined APJ with emerging markets across the Middle East, Africa, Turkey and CIS. From now on, our regional reporting will cover these regions: Americas, Europe, Greater China and EMEA or Asia Pacific, Middle East and Africa. Revenue in the Americas came to $605 million, a 5% sequential increase from Q4 2022, and it beat what we had expected thanks to NovaSeq X shipments that were stronger than anticipated. For the region, revenue fell 6% compared with a year ago, because of the anticipated drop in research caused by the slowing of COVID surveillance and slower recruitment for certain large research projects; in the Americas, demand for NextSeq 1K, 2K remains strong, with instrument shipments rising more than 20% from a year ago. Europe revenue of $261 million amounted to a 9% year-over-year decline, or a 4% decline in constant currency terms, net of hedge effects. Growth in clinical, led by oncology testing, was more than outweighed by the anticipated drop in COVID surveillance revenue as well as fewer high-throughput instrument shipments resulting from NovaSeq X supply constraints during the first quarter. Greater China revenue of $91 million amounted to a 28% year-over-year decline, or a 23% decline in constant currency terms, net of hedge effects. That year-over-year drop came mainly from ongoing COVID disruptions along with liquidity and funding constraints among our customers. This led to reduced sequencing consumables revenue and fewer mid-throughput shipments than a year earlier; through the remainder of the year, we will keep watching market headwinds in China closely and working to mitigate them. Lastly, EMEA revenue of $119 million fell 27% year-over-year, or 23% in constant currency terms, net of hedge effects. As we anticipated, the year-over-year decrease stemmed mainly from a large research project in Japan finishing, reduced COVID surveillance revenue and fewer NovaSeq 6000 instrument shipments, with only partial offset from NovaSeq X shipments since demand in the region was greater than supply. EMEA revenue was also affected by sanctions that limit our ability to do business in Russia; we anticipate the sanctions impact will last through 2023 and have built roughly $60 million in lower sequencing consumables revenue expectations for the region and our outlook for 2023 into our figures. Now on to the rest of the Core Illumina P&L. For Core Illumina, our non-GAAP gross margin came in at 65.2%, which is a drop of 500 basis points compared to the same period last year. The main reasons were less leverage on fixed costs because we had lower manufacturing volumes, plus reduced instrument margins stemming from the NovaSeq X launch — something you'd normally see when bringing a new platform to market. As we ramp up NovaSeq X production and keep pushing operating efficiencies, we anticipate gross margins will climb sequentially over the course of the year. Core Illumina non-GAAP operating expenses reached $514 million, an increase of $9 million from a year ago, largely because of the full-year effect of the headcount we added during 2022. Those non-GAAP operating expenses ended up below what we had projected, thanks to initiatives aimed at containing costs. Now let's shift to GRAIL's financial results. GRAIL brought in revenue of $20 million during the quarter, which represents 100% growth versus the prior year, mostly fueled by faster uptake of Galleri. GRAIL revenue did fall on a sequential basis, which was anticipated, because Q4 2022 included a milestone payment tied to MRD pharma partnerships. GRAIL non-GAAP operating expenses came to $173 million, up $34 million from the same quarter last year, mainly from ongoing investments in clinical trials and expanding GRAIL's commercial team. Turning now to consolidated cash flow and balance sheet items. Operations generated $10 million in cash flow. Capital expenditures for the first quarter of 2023 totaled $52 million, while free cash flow was negative $42 million.

Joydeep Goswami

executive
#5

No shares of common stock were bought back during the quarter. At the close of the quarter, we held roughly $1.5 billion in cash, cash equivalents, and short-term investments. In Q1, $500 million went toward paying off the principal balance on our 2023 term notes, which came due in March. Turning to our 2023 guidance: we continue to anticipate consolidated revenue growth of 7% to 10% for the full year 2023, which includes growth of 6% to 9% in Core Illumina revenue. Keep in mind, these ranges incorporated an expected COVID surveillance headwind of about 200 basis points, plus a year-over-year headwind from foreign exchange rates. For GRAIL, revenue is still projected to land between $90 million and $110 million in 2023. Our 2023 revenue outlook now incorporates these offsetting factors: first, reduced revenue in EMEA stemming from sanctions that impact our capacity to do business in Russia; second, an uptick in our NovaSeq X shipment expectations to over 330 instruments; and third, greater contributions from our strategic partnerships tied to drug discovery. As we've said before, we anticipate Core Illumina revenue will ramp sequentially on a quarterly basis throughout 2023, with linearity trends comparable to 2017, the year we introduced the NovaSeq 6000, when roughly 54% of total revenue was delivered in the second half, comprising about 26% in Q3 and the rest in Q4. Our 2023 revenue ramp rests on these assumptions: first, quarterly growth in NovaSeq X shipments as manufacturing capacity expands each quarter; second, sequencing consumables revenue rises as NovaSeq X customers begin projects in the latter half of 2023; and third, certain macroeconomic headwinds ease in the second half of 2023, among them a rebound from COVID disruptions in China; for fiscal 2023, at the midpoint of our revenue guidance, we now anticipate Core Illumina sequencing instrument revenue growth of about 13% year-over-year, which reflects our increased NovaSeq X shipment expectations. We now anticipate Core Illumina sequencing consumables revenue growth of roughly 5.5% year-over-year, driven mainly by our reduced revenue outlook for EMEA stemming from sanctions that impact our capacity to do business in Russia. We still anticipate Core Illumina sequencing revenue growth of approximately 8% year-over-year; this now reflects a greater contribution from sequencing service and other revenue, largely because of increased contributions from strategic pharma partnerships. We still anticipate non-GAAP earnings per diluted share between $1.25 and $1.50 for 2023, including a consolidated non-GAAP operating margin of about 8% and a Core Illumina non-GAAP operating margin of about 22%. We are reaffirming all remaining financial guidance for fiscal 2023 that was provided on February 7, 2023. Now turning to the second quarter of 2023. For the second quarter of 2023, our consolidated revenue guidance sits between $1.15 billion and $1.17 billion. At the midpoint, that works out to roughly a 670 basis point sequential gain over Q1 2023, or about $70 million. Several factors drive that: NovaSeq X instrument shipments rising quarter over quarter as our manufacturing capacity keeps ramping, ongoing sequential growth in sequencing consumables and service revenue as newly installed instruments come online, and higher GRAIL revenue quarter over quarter thanks to faster Galleri adoption. Partly offsetting those gains is a sequential drop in microarrays revenue tied to historical seasonality. At the midpoint of that revenue guidance range, we anticipate non-GAAP diluted EPS for the second quarter of roughly $0.01, which implies a consolidated non-GAAP operating margin of about 1% and a Core Illumina non-GAAP operating margin of about 17%. Those margin figures account for a quarter-over-quarter rise in Core Illumina operating expenses, which stems from higher compensation-related costs tied to our customary annual equity grant and merit adjustment in March. As revenue ramps and we scale NovaSeq X production while leveraging the fixed cost of our manufacturing base, we still anticipate operating margins strengthening during the back half of 2023. Going forward, we are committing to Core Illumina non-GAAP operating margins of 25% in 2024 and 27% in 2025. Starting later in 2023, Illumina will cut annualized run rate expenses by over $100 million. Those savings will speed our progress toward stronger margins and free up capital so we can invest more in high-growth areas. A mix of several actions will deliver these savings. We will take advantage of the recent modularization of R&D innovation that came out of NovaSeq X development, such as XLEAP-SBS and new flow cell technology, to bring down cost and shorten time to market for upcoming platforms. Further savings will come from using our global footprint and moving activities to hubs that are more cost-effective. We are also simplifying our organization and processes, which includes rationalizing the company's global real estate portfolio and third-party vendor spend, along with stepping up IT optimization efforts. The company will keep prioritizing innovations that produce highly differentiated products Illumina's customers value. I will now invite the operator to open the line for Q&A. Thank you.

Puneet Souda

analyst
#6

Starting with the order book, it's encouraging to see growth there, but I just wanted to hear your outlook regarding the broader funnel you're observing. Might that figure of 330 keep growing as the year progresses? And could you help us grasp your capacity to scale up production and deliveries throughout the year? What kind of quarterly pace should we expect for installations? Then, if I can ask something on GRAIL, more about operations and execution. I mean, historically at Illumina the product cycle has been prioritized over all else, but there are simply several diversions when it comes to the legal side with the European Commission and FTC, and now an activist campaign too. So I'm curious whether any of that jeopardizes the product cycle and the execution you've got going? Or how distinct are these initiatives? I value the answers on those. And then if I could also inquire about biotech funding. There have been inquiries about that from a peer earlier today. I'm just wondering whether you're noticing any effect from emerging biotechs? And is that factored into your guidance?

Francis deSouza

executive
#7

Great. Thanks, Puneet. You raised a few questions there; so let me go through them one by one. So the first question concerned the X and the order book for the X and the pipeline we're seeing for the X. And your question was, well, 330, might it truly rise? And I believe, in this case, the truth is that 330 will be constrained more by manufacturing than by demand. I think it's the impression we're getting at present that there's an enormous amount of enthusiasm for getting the X into customers' hands throughout our customer base. As you know, we always anticipated research customers would be among the most aggressive early adopters, and we thought clinical would trail somewhat, but we're not witnessing that this time. We're seeing robust demand from clinical customers too as they seek to launch new offerings on the X and broaden into more sequencing-intensive offerings; and you also heard that we're seeing robust demand from new to Illumina, new to high-throughput customers. And so we expect that we'll keep sort of building the demand and will be somewhat limited by how many Xs we can send out the door throughout this year. We were very heartened by the scaling up of our manufacturing and operations teams in Q1. And as you saw, we managed to ship 67 instruments, comfortably ahead of the guide we had of 40 to 50 instruments in Q1. So manufacturing is scaling, I see the teams are doing a terrific job. We are scaling that up to 80 in Q2. And so a nice little step up from Q1. We're going to move ahead in stages throughout the year until we reach that 330. So if we can expand production even more effectively than that, we will definitely provide updates — keep all of you informed; regarding — as you mentioned, plenty is happening. Clearly, everyone is watching the X for us. The X is what defines this year, and this is Illumina doing what we enjoy doing, what we excel at, bringing a high-throughput instrument to market. So even though it appears that much is happening with the regulatory process and similar matters, the truth is only a very tiny portion of the company is actually engaged in that. And the overwhelming, overwhelming, overwhelming bulk of our time and focus at Illumina goes toward and getting our products out, and really the main attention is on the X at this moment. The other question — pardon me, you had a question, one final item. So let me just remind you, do you have a question regarding biotech funding. From where we sit, our direct exposure to small- and mid-cap biotech funding companies is extremely limited. And so we do not anticipate that having any sort of material effect on our revenue throughout this year.

Dan Brennan

analyst
#8

Congratulations on the impressive beginning to this year. Perhaps regarding the X, might you provide some detail about the concept of the replacement ratio, just at this early stage based on what the order book shows so far? How is that developing when it comes to current NovaSeq customers placing orders for the X? Tied somewhat to that, another thing people ask us about often is that the X greatly increases capacity. So I'm just curious, at this early point, clearly, we'll find out what the volume turns out to be as we move through the current year and the next one, but how are you thinking about customers as they consider purchasing the X and then filling it? Do they have any — is that acting as a constraint? It doesn't seem to be. And then the last item, regarding GRAIL, Francis. How ought we to think — you have 3 separate regulatory rulings still outstanding, and you're in the midst of all that, with the EU directive probably arriving shortly. In your view, what is the most probable result for GRAIL that investors ought to be expecting, and roughly when will that become clear?

Francis deSouza

executive
#9

Excellent. Thanks, Dan, for asking. So let's begin with the X. Yes, an extremely robust beginning to this year. We're genuinely thrilled about it. And we invested considerable effort building models for what to anticipate regarding how many Xs the market might take in over the coming years. And there are multiple frameworks for considering it, correct? One approach is to adopt the static perspective as of today and ask, all right, if we simply get a conversion from an upgrade cycle going from the 6000 to Dx, what might that imply? Then you must factor in the count of customers arriving at the X as newcomers to Illumina and newcomers to high-throughput. But allow me to begin there and, once more, assuming — and I'll address elasticity shortly, yet let's set elasticity to one side for now; and so you might recall, we had this same conversation regarding the 6000, asking, well, how should one think about the upgrade cycle and how many units would be required to fulfill it? And there are a few approaches available. You might begin with capacity and consider what the ratio is for every X, how many 6000s does it displace? But honestly, we believe the superior approach is to reason from the customer outward. What I mean is that we have approximately perhaps 1,000 customers who are our high-throughput buyers, and roughly 750 among them possess just one 6000. Consequently, for those 750, purchasing less than one X is possible. So you can regard those 750 as needing to acquire an X. And so once more, even if their need for sequencing doesn't grow past what it is today — which, naturally, it will, and we'll capture elasticity — you can see they'd need 750 immediately to cover that customer base. After that, those 250 who own several 6000s will use their own kind of conversion rate; and then, naturally, there's the elasticity we're capturing, correct? As we mentioned during the call, most buyers of the X choose it because they're after the elasticity tied to a lower cost per sequencing; consequently, clinical clients describe new applications they wish to pursue that become possible mainly thanks to that cheaper sequencing price; take the solid tumor oncology testing client now aiming to move into liquid biopsy, aware they can get — it requires 12 to 15x more sequencing, yet they can reach the X's price point to make it feasible within their reimbursement constraints. Then there are clients wanting bigger research studies involving single cell or spatial. All of that sits on top of the baseline figures I just described, where folks simply upgrade directly. Regarding the GRAIL regulatory path, here's how we see it: everything reaches a climax near the close of this year and the start of next year, since we anticipate rulings on the 2 key appeals within that window; in Europe, we look for a ruling on the jurisdiction appeal during that period. Meanwhile in the U.S., you may have noticed that last week, the U.S. Fifth Circuit Court of Appeals granted us expedited review for our appeal challenging the FTC. That boosts our confidence the ruling arrives perhaps somewhat sooner than originally expected, though definitely within the window of late this year or early next year. So we anticipate the entire legal proceeding concludes in that period. Broadly, concurrently, we have — there's a divestiture work stream we launched some time back, and that effort remains fully on track to keep advancing along the divestiture route. We await the divestiture order from the European Commission, which should arrive soon. That track will therefore proceed in parallel, during the same window in which the appeals unfold.

Joydeep Goswami

executive
#10

Francis, let me build on what you said regarding clinical elasticity, okay? What you're saying is completely correct — these represent brand-new applications. Generally speaking, the signatures involved tend to be quite complex, calling for elevated sequencing levels. And since Illumina supplies tools along with reagents, we begin generating revenue the moment those clinical trials get underway, well before the tests become available on the public market, correct? That means our elasticity really kicks in even ahead of the test arriving in the market.

Dan Arias

analyst
#11

Could I simply add a question regarding those remarks about elasticity? What I'm asking is whether you anticipate that showing up in a meaningful way during the latter half of the year, specifically because it might add to consumables growth for the full year? In January, at the time you provided the outlook, elasticity was one of the stated explicit drivers behind the 8% consumables growth. So I'm just attempting to grasp where we stand when it comes to considering installation timing and the ramp on usage that would let you genuinely observe it in the second half of the year, and that would let you rely on it adding to the overall target for the year?

Joydeep Goswami

executive
#12

Yes, Dan, that is precisely correct. As we said, we anticipate that installations and the initial work customers perform to bring up their workflows will occur as we move into Q2 and Q3; and during Q4, we began to observe certain of these projects ramping up, along with customers building inventory and starting to earnestly shift toward their excess workflows platform.

Joydeep Goswami

executive
#13

Nope, that's fine. My guess is the inquiry concerned the excess, and ideally that clears it up.

Vijay Kumar

analyst
#14

I've got a few things on the guidance. Joydeep, I suppose, could you put a number on the Russia headwind, the incremental piece? And then on guidance as well, gross margins declined quarter over quarter. We're seeing something under 65. Could you discuss what shifted sequentially versus the Q4 figure of 66 and change? That's a drop of a couple hundred basis points. And looking at the operating margin outlook for 2Q, with the first half at 17%, I believe the back half requires 26%, 27% for Core Illumina to reach the annual guide — what causes that 17% to step up to roughly 27% in the back half?

Joydeep Goswami

executive
#15

Yes. Vijay, thanks for asking, and nice work — you did that math quickly. Let me begin with the easy one about the Russia headwind. As we mentioned on the call, it's roughly $60 million across the full year and about $18 million of year-over-year headwind in Q2. You're correct that gross margins declined sequentially for us in Q1. In fact, we had flagged some of this when we provided our guide in February. There are 2 particular causes. First, obviously, is the Xs launch. We told you the X is still early in its ramp, so margins on it are low. And obviously, we sold a larger number of Xs than we expected in Q1. The second cause, as you move from Q1 to Q — sorry, from Q4 to Q1, is that you normally get lower absorption in our factories, correct? So that usually produces a quarter-over-quarter gross margin decline as you go from Q1 — Q4 to Q1. Regarding operating margin for Q2, there are a few factors at play, right? As I said on the call, we had our usual salary and promotional adjustments plus equity adjustments. So as you go from Q1 to Q2, there's a onetime increase in total operating expense. But naturally, that stabilizes afterward for the remainder of the year. The second factor in Q2 for margins is that, because of the Russia situation, we again have a shift toward a greater number of instruments being sold, which affects gross margin. Together, those two offset part of the operating leverage we're achieving, keeping margins at 17%. Now you're completely right. We said on our call that we anticipate margins improving during the second half of the year. The two main drivers for that are really that as we scale up and begin enhancing margins on the X, and naturally consumables then ramp up, we get a sequential step-up each quarter. And as a result, absorption in our factories gets better, which drives higher gross margin. Also, when this year wraps up, our expectation is that gross margins will sit up in the high 60s, while operating margins land near those high 20 figures you mentioned.

Tejas Savant

analyst
#16

So Francis and Joydeep, perhaps a few on the Core side, then a few on GRAIL. Regarding the Core business, you've got that pleasant beat on X shipments, clearly relative to the guidance you gave earlier this year. Yet instrument revenue basically matched what we had modeled. So Joydeep, on the arithmetic there, was the offset really the softness in EMEA combined with NextSeq 550 placements in China? Or did greater-than-anticipated discounting, or something similar, show up somewhere else in the portfolio? Next, Francis, on NextSeq, any fresh perspective on the per GB price point you'll need to reach once XLEAP arrives on that platform next year? Competitors sit at about $2 per gig. So is 4 to 5 a reasonable ballpark in your view? Or might it land even above that, given how much inertia there is around switching? Then, on GRAIL, what we hear constantly is: how dedicated are you to divesting this asset? If you prevail in that jurisdictional appeal and recover the European Commission fine, in other words, what detail can you offer about the scenarios in which you might choose to retain GRAIL? Is it basically tied to what an IPO or a sale would fetch for the asset? Or just take us through how you're thinking about it?

Joydeep Goswami

executive
#17

Yes. Let me handle the instrument question first; yes, we felt good about the greater supply of NovaSeq X; and as noted during the call, the main offset on instruments came from the mid-throughput instrument cycle. That was again largely attributable to fewer 550 shipments, chiefly within China; regarding pricing, I want to be very clear, we monitor pricing quite closely. We see no divergence from anticipated prices, nor any decline in the prices we monitor, for both instruments and consumables; so they sit precisely where we expected them to be. And I think the next question was, was it out to GRAIL and or...

Francis deSouza

executive
#18

Moving on to the next question — perhaps I should step in and address NextSeq, specifically what kind of effect XLEAP-SBS might have on it. Tejas, as you're aware, once we bring XLEAP-SBS onto NextSeq, several fairly striking enhancements will become apparent. First, you'll notice better pricing tiers for NextSeq, and I'll circle back to that since it's the heart of your question. Beyond that, though, you'll see gains in other areas too, correct? I mean the chemistry's real-world performance when it comes to quality, and so forth. On top of that, you'll clearly get sustainability advantages, which matters a great deal to our customers, since XLEAP-SBS chemistry removes the need for a cold chain during shipment of consumables. For our customers, that translates into very substantial savings when it comes to the product's sustainability value proposition. Regarding how we approach pricing, our thinking is — and we aren't raising prices at this moment, but our thinking is that we want to set pricing in a way that lets us capture the largest possible market opportunity; so obviously, prices are going to come down. That said, our products carry capabilities in the market that are unique, not just the sustainability characteristics I mentioned, but also the onboard compute that comes from having FPGAs integrated into NextSeq. We likewise offer onboard storage optimization, something else that sets Illumina's NextSeq apart from every other mid-throughput instrument available. So prices will come down, but we'll also account for the extra value our instruments deliver; that forms part of the calculation behind the final pricing, and it will center on whatever widens the market most within the mid-throughput segment. Turning to GRAIL, so the pass-through divestiture is — to answer your question about the divestiture and then under what circumstances would you retain GRAIL? The route to divestiture is, clearly, the divestiture order will be issued soon, which will set out the process and structure of the divestiture, we have a divestiture team, already working with the team at the European Commission, and we'll proceed with that process. Simultaneously, we have 2 appeals underway. Should we lose either appeal, we'll divest promptly in the best interest of our shareholders. And we expect that to unfold, again, in that late this year, early next year sort of window, running alongside the appeals taking place. Under what circumstances would we hold onto it? If we prevail on both appeals and at that point, we get an opportunity to sort of examine the asset and sort of confirm that the assumptions in the business case we built do hold up regarding keeping it versus divesting it. So in that case, we would retain the asset and fold it in.

Julia Qin

analyst
#19

To start, when it comes to the targets you've set for operating margin, could you walk us through how the upside and downside cases might play out? Within those figures, do you build in an assumption that production of NovaSeq X done in-house gets to peak efficiency by the close of '24, or is it the close of '25? On the R&D efficiency side, could you go deeper and give us a sense of how large the gain in new product achievement would be, comparing before and after the new R&D structure is put in place? Then finally, I'd like to hear more about China. Is any offset showing up from government stimulus? And do you detect any indication of COVID-related disruption, or of recovery there?

Joydeep Goswami

executive
#20

All right; so let me — Julia, I'll handle the question on operating margin targets. I believe that breaks into 2 steps. When it comes to 2022, I'd like to reaffirm that for Core, our operating margin guidance for the year remains at 22%. A couple of offsets exist there; naturally, we're seeing a greater number of instruments in the figure for the year, once again because of some offset tied to Russia amounting to roughly $60 million for the year. Because of that, we do anticipate a modest hit to gross margin, which further productivity efforts in our manufacturing should offset; and naturally, part of the effect comes from the additional cost reductions we've put in place; as for your point on instrument or X manufacturing efficiencies, we do anticipate that before the year is over, the efficiencies we originally laid out will have been reached. Our view is that the efficiencies won't end at that point. Just as we've done across all our instruments, we keep finding more efficiencies as we move into the years that follow. So those efficiencies will keep advancing as we enter year 2, 3 of manufacture. Regarding the R&D efficiencies we mentioned, this genuinely stems from a couple of areas, and it extends past R&D, correct? On the R&D front, we've put substantial effort into making our innovations modular as part of the X, and naturally, even as part of the NextSeq 1K, 2K. And breakthroughs such as the new flow cell technology and XLEAP-SBS truly let us drastically cut the spend per platform, and for platforms that come later, and speed up their time to market. So 2023 won't show this, but '24 and beyond will. Beyond that, we're also streamlining the locations where some of our R&D happens, so we take advantage of our global footprint in hubs that cost less. That applies to R&D, but to other functions too. And then that — those sorts of activities additionally bring about more streamlining of our organization, and our processes let us rationalize our global real estate portfolio, spend, and our IT infrastructure too. So once more, what you'll observe is that beginning to show up near the close of this year, though it truly takes hold as we move into 2024 and past that. And last, when it comes to China, no advantages from any stimulus are showing up there, at least where our business is concerned. We're keeping a close watch on China, examining certain funding difficulties that our customers are up against, and we're taking action to lessen some of those difficulties.

David Westenberg

analyst
#21

Nice work on the sizable NovaSeq X rollout. I'd like to focus on that figure of 67 units. Is it the case that any of those buyers have begun retiring their 6000 machines? In the past, customers would typically wrap up their prior work before moving to the X. These days, though, there's strong consistency across the platforms. Could that pattern have shifted? Are you noticing any follow-on purchases of 6000 systems despite those customers having already migrated to X? I'm simply attempting to grasp this dynamic better.

Joydeep Goswami

executive
#22

Sure. Dave, I appreciate the question. Regarding the NovaSeq Xs, you're correct that most of our customers will move their projects gradually, and they don't plan — particularly in the clinical segment — to retire their NovaSeq 6000 units; among the first group of customers we're following from Q1 into Q2, we anticipate roughly 10 to 12 retirements as those Xs become operational. Still, retirements and replacements will represent a minor share. As the year progresses, we'll share further details on how the 6000 inventory — or rather, the 6000 installed base, not inventory — keeps changing.

Kyle Mikson

analyst
#23

Congratulations on the X launch. I've just got one question. In the past, the company's revenue growth has tended to be somewhat elevated during the 1 or 2 years after a significant sequential launch. With 6000, '17 and '18 were strong. '19 was a setback, while '14 and '15 were solid thanks to the HiSeq X. In '16, though, growth was single digit. So does anything about the NovaSeq X launch point to a different result? Or might Illumina remain caught in this sort of perennial cycle, depending on new products to drive near-term growth? Since you now face somewhat more headwinds than before, I think it would help to understand this.

Francis deSouza

executive
#24

Yes. Thank you for that question, Kyle. Perhaps I'll offer a couple of points. First, product cycles matter in our market for a couple of reasons. One, clearly they catalyze an upgrade cycle, which tends to move faster in the research market. So historically, that's been very significant for driving near-term revenue growth, since our market was mainly a research market. But as we noted last quarter, 50% of our consumables now come from the clinical market; I'd call that one growth driver, yet a major growth driver will simply be expansion in clinical use cases. We've discussed the fact that, in the clinical markets, based on the proactive runs we monitor, we're seeing continued strong growth among our clinical customers, because we're seeing greater uptake of tests such as the genetic disease testing segment, which keeps growing, or more coverage tied to oncology therapy selection, or increased NIPT coverage. So looking ahead, a significant growth driver will come more from adoption of sequencing in the clinical market rather than merely a straightforward upgrade cycle.

Joydeep Goswami

executive
#25

There's probably just one additional point worth mentioning, Kyle — you're going to notice somewhat of what tends to happen when customers switch from one system over to another, correct? There will be some shifting of consumables as they move between systems. So my view is that's not something entirely preventable. That said, Francis has it right. That pattern shows up far more among research customers than among clinical ones, isn't that so? Which means it should soften the impact.

Francis deSouza

executive
#26

We appreciate your participation. To wrap up this session, April 25 is DNA Day, marking 70 years since the double helix structure of DNA was discovered. Illumina is also celebrating its 25th anniversary this month. Throughout our company's journey, our people have made a meaningful contribution to the genomic revolution, bringing forward breakthrough innovations that sharply lower the expense of sequencing and expand who can benefit from genomics, opening new possibilities in biology and health care. Even so, at present, with just 4 million genomes having ever been sequenced — a mere 0.07% of the population — the genome era is still in its early days. That brings today's call to a close. We hope to see you at upcoming conferences and other events.

Operator

operator
#27

Appreciate it; that brings today's call to a close; thanks so much for joining us. Have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.